These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 34711813)

  • 1. Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo.
    Hitchings MDT; Ranzani OT; Dorion M; D'Agostini TL; de Paula RC; de Paula OFP; de Moura Villela EF; Torres MSS; de Oliveira SB; Schulz W; Almiron M; Said R; de Oliveira RD; Silva PV; de Araújo WN; Gorinchteyn JC; Andrews JR; Cummings DAT; Ko AI; Croda J
    Nat Commun; 2021 Oct; 12(1):6220. PubMed ID: 34711813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
    Ranzani OT; Hitchings MDT; Dorion M; D'Agostini TL; de Paula RC; de Paula OFP; Villela EFM; Torres MSS; de Oliveira SB; Schulz W; Almiron M; Said R; de Oliveira RD; Vieira da Silva P; de Araújo WN; Gorinchteyn JC; Andrews JR; Cummings DAT; Ko AI; Croda J
    BMJ; 2021 Aug; 374():n2015. PubMed ID: 34417194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
    Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP.
    Costa Clemens SA; Fortaleza CMCB; Crowe M; Tasca KI; Spadaro AG; Souza-Neto JA; Grotto RMT; Sider R; Jimeno J; Verstraeten T; Clemens R
    Front Public Health; 2022; 10():1016402. PubMed ID: 36311567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
    Clemens SAC; Folegatti PM; Emary KRW; Weckx LY; Ratcliff J; Bibi S; De Almeida Mendes AV; Milan EP; Pittella A; Schwarzbold AV; Sprinz E; Aley PK; Bonsall D; Fraser C; Fuskova M; Gilbert SC; Jenkin D; Kelly S; Kerridge S; Lambe T; Marchevsky NG; Mujadidi YF; Plested E; Ramasamy MN; Simmonds P; Golubchik T; Voysey M; Pollard AJ; ;
    Nat Commun; 2021 Oct; 12(1):5861. PubMed ID: 34615860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths.
    Meo SA; Aftab S; Bayoumy NM; Meo AS
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10133-10143. PubMed ID: 37916383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
    McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
    Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study.
    Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M
    Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study.
    Ranzani OT; Silva AAB; Peres IT; Antunes BBP; Gonzaga-da-Silva TW; Soranz DR; Cerbino-Neto J; Hamacher S; Bozza FA
    Clin Microbiol Infect; 2022 May; 28(5):736.e1-736.e4. PubMed ID: 35150884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.
    Nasreen S; Chung H; He S; Brown KA; Gubbay JB; Buchan SA; Fell DB; Austin PC; Schwartz KL; Sundaram ME; Calzavara A; Chen B; Tadrous M; Wilson K; Wilson SE; Kwong JC;
    Nat Microbiol; 2022 Mar; 7(3):379-385. PubMed ID: 35132198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study.
    Dyu T; Leung C; Simões-E-Silva AC
    Hum Vaccin Immunother; 2024 Dec; 20(1):2379865. PubMed ID: 39056147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.
    Bouillon K; Baricault B; Botton J; Jabagi MJ; Bertrand M; Semenzato L; Le Vu S; Drouin J; Dray-Spira R; Weill A; Zureik M
    BMJ Med; 2022; 1(1):e000104. PubMed ID: 36936561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study.
    Nasreen S; Febriani Y; Velásquez García HA; Zhang G; Tadrous M; Buchan SA; Righolt CH; Mahmud SM; Janjua NZ; Krajden M; De Serres G; Kwong JC
    Clin Infect Dis; 2023 Feb; 76(4):640-648. PubMed ID: 35974428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.